AnaptysBio (NASDAQ:ANAB) Upgraded at UBS Group

AnaptysBio (NASDAQ:ANAB) was upgraded by investment analysts at UBS Group to a “strong-buy” rating in a report released on Wednesday,Zacks.com reports.

Other analysts also recently issued research reports about the stock. Truist Financial boosted their target price on shares of AnaptysBio from $20.00 to $36.00 and gave the stock a “hold” rating in a research report on Monday, November 10th. Barclays cut their target price on AnaptysBio from $70.00 to $55.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 17th. Stifel Nicolaus lowered their price target on AnaptysBio from $80.00 to $56.00 and set a “buy” rating for the company in a research report on Thursday, December 11th. Guggenheim reiterated a “buy” rating on shares of AnaptysBio in a research note on Thursday, December 18th. Finally, HC Wainwright reduced their price objective on AnaptysBio from $52.00 to $51.00 and set a “buy” rating for the company in a research note on Monday, November 24th. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $60.40.

AnaptysBio Price Performance

Shares of ANAB stock opened at $43.80 on Wednesday. The stock’s fifty day moving average price is $42.46 and its 200 day moving average price is $31.30. AnaptysBio has a 1-year low of $12.21 and a 1-year high of $52.47. The company has a market cap of $1.21 billion, a price-to-earnings ratio of -15.53 and a beta of 0.32.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share for the quarter, topping the consensus estimate of ($1.06) by $1.58. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 49.94%.The business had revenue of $76.32 million during the quarter, compared to the consensus estimate of $15.83 million. As a group, equities research analysts anticipate that AnaptysBio will post -6.08 earnings per share for the current year.

AnaptysBio declared that its Board of Directors has authorized a stock repurchase plan on Friday, November 21st that authorizes the company to buyback $100.00 million in shares. This buyback authorization authorizes the biotechnology company to purchase up to 9.6% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s management believes its shares are undervalued.

Insider Buying and Selling

In other AnaptysBio news, CFO Dennis Mulroy sold 15,725 shares of the company’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $44.85, for a total value of $705,266.25. Following the sale, the chief financial officer owned 9,401 shares in the company, valued at approximately $421,634.85. This represents a 62.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director J. Anthony Ware sold 3,900 shares of AnaptysBio stock in a transaction that occurred on Tuesday, December 23rd. The shares were sold at an average price of $49.58, for a total transaction of $193,362.00. Following the transaction, the director directly owned 9,630 shares of the company’s stock, valued at approximately $477,455.40. This trade represents a 28.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 112,624 shares of company stock valued at $5,171,459 in the last three months. 33.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Larson Financial Group LLC grew its position in shares of AnaptysBio by 54.6% during the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 473 shares during the period. Rhumbline Advisers raised its holdings in AnaptysBio by 2.7% in the 1st quarter. Rhumbline Advisers now owns 30,903 shares of the biotechnology company’s stock worth $574,000 after purchasing an additional 826 shares during the period. Bessemer Group Inc. boosted its position in AnaptysBio by 950.0% during the third quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 1,292 shares in the last quarter. Corton Capital Inc. grew its holdings in AnaptysBio by 12.2% in the second quarter. Corton Capital Inc. now owns 12,004 shares of the biotechnology company’s stock valued at $266,000 after purchasing an additional 1,305 shares during the period. Finally, Tower Research Capital LLC TRC increased its position in shares of AnaptysBio by 175.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 1,377 shares in the last quarter.

Key Headlines Impacting AnaptysBio

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: Anaptys filed a partial motion to dismiss Tesaro (a GSK subsidiary)’s anticipatory breach claim in Delaware Chancery Court, which, if sustained, could reduce near‑term royalty exposure tied to Jemperli sales and lower legal risk. Reuters: AnaptysBio seeks partial dismissal GlobeNewswire: Motion to dismiss filing
• Positive Sentiment: Recent fundamentals and capital actions remain supportive: Anaptys reported an earnings and revenue beat in November and its board authorized up to $100M in share repurchases, which can support the share price over time by signaling management confidence and reducing outstanding float. MarketBeat ANAB coverage
• Neutral Sentiment: Upcoming event: CEO Daniel Faga will present at the J.P. Morgan Healthcare Conference (Jan. 13), which could catalyze new corporate updates or guidance but is unlikely to move the stock absent specific news. GlobeNewswire: JPM presentation
• Neutral Sentiment: Institutional positioning: Several funds have added or initiated positions recently, which can provide longer‑term demand but also increases the potential for large block trades to move the stock. MarketBeat ownership data
• Negative Sentiment: Insider selling: Multiple insiders (including the CEO and CFO) disclosed sizable sales on Jan. 5–7 that materially reduced their holdings; public Form 4 filings and media reports of these sales are likely contributing to today’s downward pressure as some investors view clustered insider sales negatively. InsiderTrades: insider selling alerts

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.